Hangzhou Biotest Biotech Co., Ltd, established in 2008 and headquartered in Hangzhou, China, specializes in the research, development, production, and sales of in vitro diagnostic (IVD) reagents. As a leader in China’s IVD industry, Biotest is renowned for its innovation and comprehensive product range.

The company's primary offerings include Point-of-Care Testing (POCT) rapid diagnostic reagents, making it one of the few global manufacturers with an extensive POCT product line. Biotest’s products are categorized into five main areas: drug abuse testing, infectious disease testing, fertility health testing, tumor marker testing, and cardiology marker testing. These products are widely utilized across various medical institutions, judicial testing systems, third-party testing organizations, Centers for Disease Control and Prevention (CDC), and private clinics both domestically and internationally.

Biotest’s industry achievements have earned it recognition and awards. The company was named a Hangzhou high-tech enterprise in 2013 and a national high-tech enterprise in 2019. In 2022, the RightSign brand received the honorary title of "Zhejiang Famous Export Brand" from the Zhejiang Provincial Department of Commerce. In 2023, Biotest was recognized as the Enterprise Technology Center and "Cloud Enterprise" in Zhejiang Province's manufacturing industry.

Biotest is dedicated to global market expansion. In March 2015, it acquired Advin Biotech in the United States, establishing itself as a leading technological provider of drug testing products in North America and globally. This acquisition allowed Biotest to set up a research and development and production base in the U.S., leveraging American technological strengths to deliver cutting-edge diagnostic products worldwide.